NAGE
HealthcareNiagen Bioscience, Inc.
$6.45
+$0.20 (+3.20%)
Jan 5, 2026
Price History (1Y)
Analysis
Niagen Bioscience, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $514.75M and revenue of $124.71M (TTM). The company operates on a relatively small scale, employing 104 individuals. From a financial perspective, Niagen Bioscience has demonstrated solid profitability, with gross margins reaching 63.9%, operating margins at 12.5%, and profit margins at 16.4% (TTM). Returns on equity and assets stand at 38.9% and 15.6%, respectively, indicating a strong ability to generate returns from shareholder investments. The company's balance sheet shows minimal debt ($3.06M) against substantial cash reserves ($64.14M), yielding a current ratio of 4.12. In terms of valuation, Niagen Bioscience trades at a P/E ratio and forward P/E of 25.80, reflecting a growth rate of 32.9% in revenue over the past year and 150.0% in earnings. While dividend information is not available (N/A), the payout ratio is 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Visit website →Key Statistics
- Market Cap
- $514.75M
- P/E Ratio
- 25.80
- 52-Week High
- $14.69
- 52-Week Low
- $5.16
- Avg Volume
- 922.59K
- Beta
- 2.35
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 104